A “hot” issue: TGF -β and checkpoint inhibitor resistance
In this article, Bryan Oronsky, Chief Development Officer, and Tony…
In this article, Bryan Oronsky, Chief Development Officer, and Tony Reid, Chief Executive Officer of EpicentRx, explain how AdAPT-001 uses tumour cells as a factory to make the TGF-beta trap that it carries. This trap neutralises the immunosuppressive protein, transforming growth factor–β to ‘heat up’ tumours and sensitise them to…